Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC enriched with extracellular vesicles for segmental bone defects
NCT05520125Phase 2Unknown
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of Mesenchymal stem cells enriched by extracellular vesicles in Segmental bone defect (2 arms). Primary endpoints: Adverse effects associated with the therapy at 1 year and Percent of completely recovered patients with segmental bone tissue defects at 1 year. Status: unknown.
02
Drugs
Mesenchymal stem cells enriched by extracellular vesicles
03
Conditions
Segmental bone defect
Beyond the preview
Go deeper on NCT05520125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520125.